Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Shares Outstanding (Diluted Average) (2020 - 2025)

Cardiol Therapeutics filings provide 3 years of Shares Outstanding (Diluted Average) readings, the most recent being $46.0 million for Q4 2022.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 34.29% to $46.0 million in Q4 2022 year-over-year; TTM through Dec 2022 was $46.0 million, a 34.29% increase, with the full-year FY2022 number at $46.0 million, up 34.29% from a year prior.
  • Shares Outstanding (Diluted Average) hit $46.0 million in Q4 2022 for Cardiol Therapeutics, up from $34.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $46.0 million in Q4 2022 to a low of $22.9 million in Q4 2020.
  • Median Shares Outstanding (Diluted Average) over the past 3 years was $34.3 million (2021), compared with a mean of $34.4 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 49.73% in 2021 and later skyrocketed 34.29% in 2022.
  • Cardiol Therapeutics' Shares Outstanding (Diluted Average) stood at $22.9 million in 2020, then surged by 49.73% to $34.3 million in 2021, then soared by 34.29% to $46.0 million in 2022.
  • The last three reported values for Shares Outstanding (Diluted Average) were $46.0 million (Q4 2022), $34.3 million (Q4 2021), and $22.9 million (Q4 2020) per Business Quant data.